Results 81 to 90 of about 56,913 (295)

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension

British Journal of Clinical Pharmacology, EarlyView.
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien, Burabha Pussadhamma, Sirimas Kanjanawart, Thikhumporn Areesinpitak, Nontaya Nakkam, Chingching Foocharoen, Wichittra Tassaneeyakul, Suda Vannaprasaht   +7 more
wiley   +1 more source

Effects of Danshen tablets on pharmacokinetics of amlodipine in rats

Pharmaceutical Biology, 2019
Context: Danshen tablets (DST), an effective traditional Chinese multi-herbal formula, are often combined with amlodipine (ALDP) for treating coronary heart disease.
Haixia Zhang, Xiuyuan Han, Yiqing Li, Hangao Li, Xichun Guo   +4 more
doaj   +1 more source

Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism

Pharmaceutical Biology, 2020
Context Hyperlipidaemia and hypertension are often treated together with curcumin and amlodipine. It is necessary to investigate the drug-drug interaction between curcumin and amlodipine.
Na Jiang, Meicheng Zhang, Xiangzhi Meng, Bin Sun   +3 more
doaj   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Cytochrome P450 Gene Polymorphisms and Their Influence on Antipsychotic Pharmacokinetics in Schizophrenia: A Review

Безопасность и риск фармакотерапии
INTRODUCTION. The activity of cytochrome P450 enzymes (CYP450), which play a key role in antipsychotic metabolism, influences treatment efficacy and safety.
M. O. Zhukova, N. M. Kiseleva
doaj   +1 more source

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang, Yoonjin Kim, Daye Jung, Jae Min Cho, Joo‐Youn Cho, SeungHwan Lee   +5 more
wiley   +1 more source

Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5‐year analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Careful consideration of drug–drug interactions (DDIs) is critical as people with HIV age. We analysed queries submitted to the University of Liverpool HIV Drug Interactions Database to assess changes in prescribing patterns over 5 years. Methods Queries submitted between January 2020 and December 2024 were extracted and categorized by year ...
Cecile Gras, Minh P. Le, Justin Chiong, Sara Gibbons, Daniel Seddon, Catia Marzolini, Saye Khoo   +6 more
wiley   +1 more source

Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring

British Journal of Clinical Pharmacology, EarlyView.
Lenacapavir (LEN), a first‐in‐class capsid inhibitor, has unique pharmacokinetics that enable twice‐yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug–drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant ...
Aaron S. Devanathan, Thomas Glowa, Emily M. Thompson, Amanda J. Saylor, Thomas D. Nolin, Sharon A. Riddler, Ken S. Ho   +6 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Entwicklung eines CYP3A4-abhängigen Reportergenassays

, 2011
Die Cytochrom-P450-Monoxygenase 3A4 (CYP3A4) gehört zu den wichtigsten fremdstoffmetabolisierenden Enzymen im menschlichen Organismus. Die Aktivität des Enzyms kann über die Steigerung der Genexpression oder über die Inhibierung der katalytischen ...
Luckert, C.
core